Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: guarantee (67), certify (32), warrant (16)

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description: Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of ad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommend
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommend
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Lenvatinib(60kg or greater)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

Lenvatinib(59kg or less)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

Nivolumab_240mg

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or m
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Hydration Pilots application and support pack process

Description: January Classification: Official Hydration Pilots: Application support pack & process Hydration Pilots: application support pack an
Url: /Media/Southampton-Clinical-Research/Grants/Download/Hydration-Pilots-application-and-support-pack-process.docx

711 to 720 of 1000

Previous … 70 71 72 73 74 … Next